{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:42:31Z","timestamp":1791042151353,"version":"4.1.0"},"reference-count":29,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Context: In previous 1-yr trials, treatment with pramlintide (120 \u03bcg), an analog of the \u03b2-cell hormone amylin, induced sustained reductions in A1C and body weight in insulin-using subjects with type 2 diabetes.<\/jats:p>\n                  <jats:p>Objective: To assess the potential of pramlintide as an antiobesity agent, we assessed the weight effect, safety, and tolerability of pramlintide in non-insulin-treated obese subjects with and without type 2 diabetes at doses greater than previously studied.<\/jats:p>\n                  <jats:p>Design\/Setting: We performed a randomized, double-blind, placebo-controlled, multicenter study.<\/jats:p>\n                  <jats:p>Patients: A total of 204 obese subjects [80\/20% female\/male, age 48 \u00b1 10 yr, and body mass index 37.8 \u00b1 5.6 kg\/m2 (mean \u00b1 sd)] participated in the study.<\/jats:p>\n                  <jats:p>Intervention: For 16 wk, without concomitant lifestyle intervention, subjects self-administered pramlintide (nonforced dose escalation \u2264 240 \u03bcg) or placebo via sc injection three times a day before meals.<\/jats:p>\n                  <jats:p>Main Outcome Measures: Weight, waist circumference, tolerability, and safety were the main outcome measures.<\/jats:p>\n                  <jats:p>Results: Pramlintide was generally well tolerated, with 88% of subjects able to escalate to the maximum dose of 240 \u03bcg. Withdrawal rates were similar between placebo (25%) and pramlintide-treated subjects (29%). Subjects completing 16 wk of pramlintide treatment experienced placebo-corrected reductions in body weight of 3.7 \u00b1 0.5% (3.6 \u00b1 0.6 kg; P &amp;lt; 0.001) and waist circumference (3.6 \u00b1 1.1 cm; P &amp;lt; 0.01). Approximately 31% of pramlintide-treated subjects achieved \u22655% weight loss (vs. 2% placebo; P &amp;lt; 0.001). More pramlintide than placebo-treated subjects reported improvements in appetite control (72% vs. 31%), weight control (63% vs. 24%), and overall well-being (52% vs. 17%). No unexpected safety signals were observed. The most common adverse event reported was mild, transient nausea. Pramlintide-treated subjects not reporting nausea experienced weight loss similar to those who did (3.6 \u00b1 0.5% and 3.9 \u00b1 0.5%, respectively).<\/jats:p>\n                  <jats:p>Conclusion: These results support continued evaluation of pramlintide as a potential treatment for obesity.<\/jats:p>","DOI":"10.1210\/jc.2006-2003","type":"journal-article","created":{"date-parts":[[2007,5,15]],"date-time":"2007-05-15T21:10:58Z","timestamp":1179263458000},"page":"2977-2983","source":"Crossref","is-referenced-by-count":153,"title":["Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study"],"prefix":"10.1210","volume":"92","author":[{"given":"Louis","family":"Aronne","sequence":"first","affiliation":[{"name":"Weill-Cornell Medical College (L.A.), New York, New York 10021"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Scripps Clinic (K.F.), San Diego, California 92007"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Aroda","sequence":"additional","affiliation":[{"name":"University of California, San Diego (V.A.), San Diego, California 92093"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Chen","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Incorporated (K.C., A.H., N.C.K., C.B., C.W.L., C.W.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Halseth","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Incorporated (K.C., A.H., N.C.K., C.B., C.W.L., C.W.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Kesty","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Incorporated (K.C., A.H., N.C.K., C.B., C.W.L., C.W.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Burns","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Incorporated (K.C., A.H., N.C.K., C.B., C.W.L., C.W.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron W.","family":"Lush","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Incorporated (K.C., A.H., N.C.K., C.B., C.W.L., C.W.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Weyer","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Incorporated (K.C., A.H., N.C.K., C.B., C.W.L., C.W.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613590139500_R1","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1126\/science.1109951","article-title":"The gut and energy balance: visceral allies in the obesity wars.","volume":"307","author":"Badman","year":"2005","journal-title":"Science"},{"key":"2020071613590139500_R2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1677\/joe.1.05866","article-title":"Appetite control.","volume":"184","author":"Wynne","year":"2005","journal-title":"J Endocrinol"},{"key":"2020071613590139500_R3","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1098\/rstb.2006.1858","article-title":"Pancreatic signals controlling food intake; insulin, glucagon and amylin.","volume":"361","author":"Woods","year":"2006","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2020071613590139500_R4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1467-789X.2006.00245.x","article-title":"Gut peptides and the regulation of appetite.","volume":"7","author":"Huda","year":"2006","journal-title":"Obes Rev"},{"key":"2020071613590139500_R5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1389450053174596","article-title":"Pancreatic amylin as a centrally acting satiating hormone.","volume":"6","author":"Lutz","year":"2005","journal-title":"Curr Drug Targets"},{"key":"2020071613590139500_R6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00060793-199708000-00006","article-title":"Amylin\u2019s physiology and its role in diabetes.","volume":"4","author":"Young","year":"1997","journal-title":"Curr Opin Endocrinol Diab"},{"key":"2020071613590139500_R7","first-page":"493","article-title":"High affinity amylin binding sites in rat brain.","volume":"44","author":"Beaumont","year":"1993","journal-title":"Mol Pharmacol"},{"issue":"Suppl 1","key":"2020071613590139500_R8","first-page":"A389","article-title":"Sustained reduction in food intake and body weight in high fat-fed rats during 28-day amylin infusion.","volume":"52","author":"Mack","year":"2003","journal-title":"Diabetes"},{"key":"2020071613590139500_R9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin.","volume":"37","author":"Young","year":"1996","journal-title":"Drug Dev Res"},{"key":"2020071613590139500_R10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes Res"},{"key":"2020071613590139500_R11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"2020071613590139500_R12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes.","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"2020071613590139500_R13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"2020071613590139500_R14","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial.","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"2020071613590139500_R15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","article-title":"Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.","volume":"48","author":"Chapman","year":"2005","journal-title":"Diabetologia"},{"issue":"Suppl","key":"2020071613590139500_R16","doi-asserted-by":"crossref","first-page":"163S","DOI":"10.1038\/oby.2004.283","article-title":"Long-term pharmacotherapy for obesity","volume":"12","author":"Klein","year":"2004","journal-title":"Obes Res"},{"key":"2020071613590139500_R17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial.","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"2020071613590139500_R18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","article-title":"Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.","volume":"2","author":"Finer","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"2020071613590139500_R19","first-page":"837","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).","volume-title":"Lancet [Erratum (1999) 354:602]","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998"},{"key":"2020071613590139500_R20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00024677-200302010-00004","article-title":"Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.","volume":"2","author":"Purnell","year":"2003","journal-title":"Treat Endocrinol"},{"key":"2020071613590139500_R21","article-title":"Pramlintide-treatment reduces 24-hour caloric intake and meal sizes, and improves control of eating in obese subjects: a 6-week translational research study.","author":"Smith","year":"2007","journal-title":"Am J Physiol,"},{"key":"2020071613590139500_R22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1467-789x.2000.00004.x","article-title":"Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance.","volume":"1","author":"Astrup","year":"2000","journal-title":"Obes Rev"},{"issue":"Suppl 4","key":"2020071613590139500_R23","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ijo.0802215","article-title":"Updated review on the benefits of weight loss","volume":"26","author":"Vidal","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2020071613590139500_R24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcn\/60.5.647","article-title":"Long-term weight loss: the effect of pharmacologic agents.","volume":"60","author":"Goldstein","year":"1994","journal-title":"Am J Clin Nutr"},{"key":"2020071613590139500_R25","volume-title":"Guidance for the clinical evaluation of weight-control drugs.","author":"Food and Drug Administration","year":"1996"},{"key":"2020071613590139500_R26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2165\/00003495-200464130-00003","article-title":"Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data.","volume":"64","author":"Kruger","year":"2004","journal-title":"Drugs"},{"key":"2020071613590139500_R27","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/oby.2007.626","article-title":"Low-dose pramlintide reduced food intake and meal duration in healthy, normal weight subjects.","volume":"15","author":"Chapman","year":"2007","journal-title":"Obesity"},{"key":"2020071613590139500_R28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0167-0115(97)01034-3","article-title":"Comparison of Fos induced in rat brain by GLP-1 and amylin.","volume":"71","author":"Rowland","year":"1997","journal-title":"Regul Pept"},{"key":"2020071613590139500_R29","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1210\/en.2006-0393","article-title":"Antiobesity effects of the \u03b2-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression.","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinology"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/8\/2977\/10404723\/jcem2977.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/8\/2977\/10404723\/jcem2977.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T21:07:09Z","timestamp":1594933629000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/8\/2977\/2597629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2006-2003","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}